share_log

中国生物制药(01177.HK):盐酸安罗替尼胶囊、TQB2916(CD40激动剂)、FHND6091(蛋白酶体抑制剂)共6项研究数据在2024 AACR公布

China Biopharmaceutical (01177.HK): Anlotinib hydrochloride capsules, TQB2916 (CD40 agonist), and FHND6091 (proteasome inhibitor) were announced in 2024 AACR

Gelonghui Finance ·  Apr 10 08:06

Gelonghui, April 10 | China Biopharmaceutical (01177.HK) announced that the three innovative drugs “anlotinib hydrochloride capsules,” “TQB2916 (CD40 agonist),” and “FHND6091 (proteasome inhibitor)” developed by the group have announced 6 research results at the 2024 American Cancer Association Annual Meeting (AACR).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment